Type 1 Diabetes

Pregnant women with type 2 diabetes have a greater risk for perinatal mortality vs. pregnant women with type 1 diabetes, gestational diabetes and no diabetes, researchers reported in the American Journal of Obstetrics and Gynecology.

For the second time since 2019, the oral SGLT1 and SGLT2 dual inhibitor sotagliflozin has been denied FDA approval for adults with type 1 diabetes, with elevated risk for diabetic ketoacidosis being a primary concern.

New guidance on GLP-1 receptor agonist use, how to tackle medication shortages and expanded continuous glucose monitoring use for type 2 diabetes are among the updates in the American Diabetes Association’s 2025 Standards of Care.

Use of the dual SGLT1/SGLT2 inhibitor sotagliflozin was associated with similar HbA1c reduction for patients with type 1 diabetes using insulin whether or not they also had chronic kidney disease, according to study data.

Children who attend day care are 32% less likely to develop type 1 diabetes compared with children who do not go to day care, according to a systematic review and meta-analysis published in JAMA Pediatrics.

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee recommended not approving sotagliflozin for glucose control as an adjunct to insulin in adults with type 1 diabetes and CKD.

Five years after receiving a complete response letter from the agency, Lexicon Pharmaceuticals brought sotagliflozin back before an FDA advisory panel to seek an indication to treat patients with type 1 diabetes and chronic kidney disease.

Prescriptions for GLP-1 receptor agonists and SGLT2 inhibitors for patients with type 1 diabetes rose between 2010 and 2023 despite not being approved for that population, according to a research letter published in JAMA.

Researchers found that women who slept less than 7 hours per night at 24 to 28 weeks’ gestation were more likely to have a child with neurodevelopmental delays compared with those who slept 7 hours or more per night.

The FDA has lifted a clinical hold on two trials assessing an investigational treatment for people with type 1 and type 2 diabetes, Biomea Fusion announced.